Pfizer Inc (PFE) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.010x

Based on the latest financial reports, Pfizer Inc (PFE) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($835.00 Million) by net assets ($85.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Pfizer Inc for the company's overall valuation and market capitalisation.

Pfizer Inc - Cash Flow Conversion Efficiency Trend (1989–2025)

This chart illustrates how Pfizer Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Pfizer Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pfizer Inc ranked by their cash flow conversion efficiency. Explore how high is Pfizer Inc's earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Western Digital Corporation
NASDAQ:WDC
0.124x
The Boeing Company
NYSE:BA
-0.030x
Shopify Inc
TO:SHOP
0.052x
Eaton Corporation PLC
NYSE:ETN
0.056x
Danaher Corporation
NYSE:DHR
0.033x
Banco Santander S.A
F:BSDK
0.080x
Pfizer Inc
SA:PFIZ34
0.010x
Novo Nordisk A/S
CO:NOVO-B
0.039x

Annual Cash Flow Conversion Efficiency for Pfizer Inc (1989–2025)

The table below shows the annual cash flow conversion efficiency of Pfizer Inc from 1989 to 2025. View current stock price of Pfizer Inc for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $86.78 Billion $11.71 Billion 0.135x -6.33%
2024-12-31 $88.50 Billion $12.74 Billion 0.144x +47.79%
2023-12-31 $89.29 Billion $8.70 Billion 0.097x -68.07%
2022-12-31 $95.92 Billion $29.27 Billion 0.305x -27.45%
2021-12-31 $77.46 Billion $32.58 Billion 0.421x +85.35%
2020-12-31 $63.47 Billion $14.40 Billion 0.227x +14.37%
2019-12-31 $63.45 Billion $12.59 Billion 0.198x -20.07%
2018-12-31 $63.76 Billion $15.83 Billion 0.248x +8.00%
2017-12-31 $71.66 Billion $16.47 Billion 0.230x -13.50%
2016-12-31 $59.84 Billion $15.90 Billion 0.266x +19.02%
2015-12-31 $65.00 Billion $14.51 Billion 0.223x -5.28%
2014-12-31 $71.62 Billion $16.88 Billion 0.236x +1.67%
2013-12-31 $76.62 Billion $17.77 Billion 0.232x +11.05%
2012-12-31 $81.68 Billion $17.05 Billion 0.209x -14.77%
2011-12-31 $82.62 Billion $20.24 Billion 0.245x +88.78%
2010-12-31 $88.27 Billion $11.45 Billion 0.130x -29.24%
2009-12-31 $90.45 Billion $16.59 Billion 0.183x -41.94%
2008-12-31 $57.74 Billion $18.24 Billion 0.316x +54.05%
2007-12-31 $65.12 Billion $13.35 Billion 0.205x -17.58%
2006-12-31 $70.72 Billion $17.59 Billion 0.249x +12.05%
2005-12-31 $66.36 Billion $14.73 Billion 0.222x -6.40%
2004-12-31 $68.88 Billion $16.34 Billion 0.237x +32.11%
2003-12-31 $65.38 Billion $11.74 Billion 0.180x -64.82%
2002-12-31 $19.95 Billion $10.18 Billion 0.510x +0.80%
2001-12-31 $18.29 Billion $9.26 Billion 0.506x +31.40%
2000-12-31 $16.08 Billion $6.20 Billion 0.385x -60.25%
1999-12-31 $3.15 Billion $3.06 Billion 0.970x +191.62%
1998-12-31 $8.81 Billion $2.93 Billion 0.332x +68.95%
1997-12-31 $8.28 Billion $1.63 Billion 0.197x -33.32%
1996-12-31 $7.00 Billion $2.07 Billion 0.295x -10.02%
1995-12-31 $5.55 Billion $1.82 Billion 0.328x -3.87%
1994-12-31 $4.36 Billion $1.49 Billion 0.341x +5.48%
1993-12-31 $3.90 Billion $1.26 Billion 0.323x +90.52%
1992-12-31 $4.75 Billion $807.00 Million 0.170x +1.36%
1991-12-31 $5.06 Billion $847.60 Million 0.167x -0.33%
1990-12-31 $5.12 Billion $860.50 Million 0.168x +16.84%
1989-12-31 $4.56 Billion $655.80 Million 0.144x --

About Pfizer Inc

NYSE:PFE USA Drug Manufacturers - General
Market Cap
$157.54 Billion
Market Cap Rank
#159 Global
#91 in USA
Share Price
$27.64
Change (1 day)
+0.66%
52-Week Range
$23.60 - $29.02
All Time High
$53.48
About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more